How much did Spravato (esketamine) bring in during 2023?
Public company disclosures tying Janssen (J&J) to specific, full-year “Spravato” sales for 2023 are not provided in the materials available here. As a result, I can’t state a verified 2023 revenue figure for Janssen’s Spravato from the information currently on hand.
Where can I find verified 2023 Spravato (Janssen) sales figures?
To get an exact number, you typically need Janssen’s parent company reporting in J&J’s annual filings or investor materials that break out Spravato revenue (or esketamine) by product. If you share the specific document or excerpt you’re using (e.g., J&J 2023 Form 10-K table, an investor presentation, or a link), I can help extract and interpret the 2023 sales figure.
Are “Spravato sales” the same as “Janssen sales”?
No. Janssen’s overall sales cover many products and divisions. “Spravato sales” are the revenue for the esketamine nasal spray product only, which may be reported under a specific segment or product line (depending on the period and reporting format).
If you meant global vs. U.S. sales, which one?
“Spravato sales” can be reported for different scopes (U.S. only, global, or by region). The exact 2023 number depends on which geography and reporting basis you mean.
Quick check: what exactly should I report?
Reply with one of the following so I can give you the right figure:
1) Global Spravato sales in 2023
2) U.S. Spravato sales in 2023
3) Janssen segment revenue that includes Spravato (not just Spravato)
Also paste the link or table from the source you’re using, and I’ll calculate or quote the 2023 sales precisely.